- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Enhancing Accessibility: Ruxolitinib Cream and Improved Patient Access
Lisa Swanson, MD, FAAD, sheds light on the enhanced accessibility of ruxolitinib cream, highlighting its improved availability for patients in need.
EP: 1.Expert Insights: Unmet Needs in Topical Treatment for Atopic Dermatitis
EP: 2.Rapid Itch Relief With Topical Ruxolitinib: A Dermatological Perspective
EP: 3.Safety and Access Considerations: Topical Ruxolitinib Review
EP: 4.Clinical Perspectives: Addressing Unmet Needs in Topical Atopic Dermatitis Treatment
EP: 5.Understanding Efficacy and Real-World Application of Topical Non-Steroidal Treatments for AD
EP: 6.Insights on Topical Ruxolitinib: Rapid Itch Relief and Pediatric Considerations in Atopic Dermatitis
EP: 7.Ruxolitinib Cream vs. Corticosteroids in AD: Commentary on Location-Specific Safety and Continuous Use Potential
EP: 8.Enhancing Accessibility: Ruxolitinib Cream and Improved Patient Access
This is a video synopsis of a discussion involving James Del Rosso, DO, a dermatologist practicing in Las Vegas, Nevada, Brad Glick, DO, MPH, FAAD, a principal investigator at GSI Clinical Research in South Florida, and Lisa Swanson, MD, FAAD, a dermatologist and pediatric dermatologist based in Boise, Idaho.
The panelists delve into the challenges and advancements regarding access to topical ruxolitinib for treating atopic dermatitis (AD). Dr. Del Rosso emphasizes the initial difficulties in accessing the medication but highlights significant improvements, particularly in Idaho, Florida, and Nevada. He underscores the efficacy of ruxolitinib in addressing mild to moderate AD and encourages patients to revisit the option.
Dr. Swanson offers assistance to individuals facing access issues, highlighting her willingness to aid in navigating the process. Dr. Glick mentions the availability of preform letters from the American Academy of Dermatology's Practice Management Center.
The panelists express optimism about the evolving treatment landscape, particularly with the advent of new systemic therapeutics. They commend the effectiveness of ruxolitinib and the increased availability of samples, emphasizing the importance of persistence in overcoming initial obstacles. The discussion concludes with appreciation for the opportunity to collaborate and share insights on managing AD effectively.
Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.
